Valuation: Verona Pharma plc

Capitalization 6.38B 8.6B 7.46B 7.02B 11.81B 745B 13.3B 83.18B 31.83B 341B 32.26B 31.57B 1,254B P/E ratio 2025 *
184x
P/E ratio 2026 * 37.1x
Enterprise value 6.24B 8.41B 7.29B 6.87B 11.55B 728B 13.01B 81.36B 31.14B 334B 31.55B 30.88B 1,227B EV / Sales 2025 *
20.2x
EV / Sales 2026 * 11.2x
Free-Float
68.7%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.74%
1 week+2.30%
Current month+16.16%
1 month+27.30%
3 months+41.18%
6 months+124.46%
Current year+103.10%
More quotes
1 week 89.69
Extreme 89.69
94.45
1 month 71
Extreme 71
94.45
Current year 43.44
Extreme 43.44
94.45
1 year 14.14
Extreme 14.14
94.45
3 years 3.99
Extreme 3.99
94.45
5 years 3.41
Extreme 3.4078
94.45
10 years 0
Extreme 0
94.45
More quotes
Manager TitleAgeSince
Chief Executive Officer 60 2020-01-31
Director of Finance/CFO 62 2020-02-29
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 70 2014-11-30
Director/Board Member 72 2015-09-09
Director/Board Member 69 2015-09-09
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.74%+2.30%+528.80%+2,349.87% 8.6B
-0.75%-3.69%-51.60%-13.26% 53.86B
-0.44%-6.27%+26.71%+39.26% 33.16B
+0.52%-4.39%+61.20%-33.18% 26.05B
+2.04%-0.04%+25.86%-13.57% 26.23B
+3.24%+4.00%+51.02%+429.82% 19.5B
+1.98%+3.94%+159.27%+1,956.00% 15.27B
-1.78%-7.02%-23.75%-34.58% 13.11B
0.00%-13.93%+107.76%-66.10% 12.49B
-0.91%-2.93%+81.85%+108.63% 11.01B
Average +0.76%-2.83%+96.71%+472.29% 21.93B
Weighted average by Cap. +0.48%-3.05%+46.92%+263.29%
See all sector performances

Financials

2025 *2026 *
Net sales 310M 417M 362M 341M 573M 36.14B 646M 4.04B 1.55B 16.56B 1.57B 1.53B 60.87B 548M 738M 640M 603M 1.01B 63.91B 1.14B 7.14B 2.73B 29.28B 2.77B 2.71B 108B
Net income 16.89M 22.76M 19.74M 18.59M 31.25M 1.97B 35.21M 220M 84.26M 903M 85.38M 83.57M 3.32B 178M 240M 208M 196M 329M 20.75B 371M 2.32B 887M 9.51B 899M 880M 34.94B
Net Debt -139M -187M -162M -153M -257M -16.21B -290M -1.81B -693M -7.42B -702M -687M -27.29B -248M -334M -290M -273M -459M -28.95B -517M -3.23B -1.24B -13.26B -1.25B -1.23B -48.76B
More financial data * Estimated data
Logo Verona Pharma plc
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Employees
209
More about the company
Date Price Change Volume
25-06-20 94.32 $ +3.74% 1,089,843
25-06-18 90.92 $ -2.16% 1,008,667
25-06-17 92.93 $ +0.25% 1,158,927
25-06-16 92.70 $ +0.54% 974,611
25-06-13 92.20 $ -0.32% 754,465

Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
94.32USD
Average target price
103.10USD
Spread / Average Target
+9.31%
Consensus

Quarterly revenue - Rate of surprise